What development phase is DOPEXAMINE in?

DOPEXAMINE is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

DOPEXAMINE

FDA-approved active Small molecule Quality 10/100

At a glance

Generic name	DOPEXAMINE
Drug class	dopexamine
Target	Beta-2 adrenergic receptor, D(1A) dopamine receptor
Modality	Small molecule
Therapeutic area	Cardiovascular
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Assessment of the Effects of Pressors on Graft Blood Flow After Free Tissue Transfer Surgery (PHASE4)
Dopexamine and Norepinephrine Compared With Epinephrine Alone in Septic Shock (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

DOPEXAMINE CI brief — competitive landscape report
DOPEXAMINE updates RSS · CI watch RSS